AR012304A1 - Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.

Info

Publication number
AR012304A1
AR012304A1 ARP980101486A ARP980101486A AR012304A1 AR 012304 A1 AR012304 A1 AR 012304A1 AR P980101486 A ARP980101486 A AR P980101486A AR P980101486 A ARP980101486 A AR P980101486A AR 012304 A1 AR012304 A1 AR 012304A1
Authority
AR
Argentina
Prior art keywords
compositions
treatment
treatments
composition
methods
Prior art date
Application number
ARP980101486A
Other languages
English (en)
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Publication of AR012304A1 publication Critical patent/AR012304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion provee un método y composiciones para medicamentos utilizados para tratar las enfermedades intestinales inflamatorias, formuladascon tres o mas agentes micobacterianos atípicos. La invencion provee además combinaciones deagentes micobacterianos anti-atípicos efectivos contra lascepas micobacterianas atípicas. Provee también un método para potenciar los agentes amicobacterianos anti-atípicos en el tratamiento de la enfermedadintestinal inflamatoria inmunizando pacientes con extractos de micobacteria no-patogénica.
ARP980101486A 1997-04-01 1998-04-01 Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos. AR012304A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
AR012304A1 true AR012304A1 (es) 2000-10-18

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101486A AR012304A1 (es) 1997-04-01 1998-04-01 Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.

Country Status (16)

Country Link
US (1) US6277836B1 (es)
EP (1) EP0971735B1 (es)
JP (3) JP2001524951A (es)
AR (1) AR012304A1 (es)
AT (1) ATE389417T1 (es)
CA (1) CA2285923C (es)
CY (1) CY1109783T1 (es)
DE (1) DE69839261T2 (es)
DK (1) DK0971735T3 (es)
ES (1) ES2303351T3 (es)
IL (1) IL132145A (es)
NO (1) NO325947B1 (es)
NZ (1) NZ500696A (es)
PT (1) PT971735E (es)
SI (1) SI0971735T1 (es)
WO (1) WO1998043667A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
CA2367575A1 (en) * 1999-02-12 2000-08-17 Washington University Stimulating neutrophil function to treat inflammatory bowel disease
JP4803935B2 (ja) 1999-10-08 2011-10-26 アフィニアム・ファーマシューティカルズ・インコーポレイテッド Ｆａｂｉ阻害剤
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
BR0109544A (pt) * 2000-03-28 2003-06-10 Biochemie Gmbh Partìculas granuladas com sabor ocultado
DE60140491D1 (de) 2000-08-29 2009-12-24 Biocon Ltd Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
ATE420640T1 (de) * 2001-04-06 2009-01-15 Affinium Pharm Inc Fab-i-inhibitoren
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US7790709B2 (en) * 2002-12-06 2010-09-07 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
WO2005072113A2 (en) * 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
CA2555304C (en) 2004-02-06 2016-06-28 Nicolas Peter Shortis Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
KR20130028807A (ko) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 방사선 유발성 장염의 예방, 치료 및 개선 방법
DK1828167T3 (da) 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN103948609A (zh) * 2005-08-24 2014-07-30 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
CA2658506C (en) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
WO2009064953A1 (en) * 2007-11-15 2009-05-22 Enanta Pharmaceuticals, Inc. Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
US8343511B2 (en) 2008-02-08 2013-01-01 Red Hill Biopharma Ltd. Methods and compositions for treating inflammatory bowel disease
BRPI0911998A2 (pt) * 2008-05-01 2015-10-13 Procter & Gamble métodos e kits para o tratamento de condições de desordem inflamatória intestinal
WO2011044140A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
AU2010312309B2 (en) 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
BR122014009845A2 (pt) 2010-04-26 2015-12-29 Salix Pharmaceuticals Ltd usos de balsalazida para preparação de composição farmacêutica para tratamento de distúrbio gastrointestinal e induzir remissão clínica de colite ulcerativa em indivíduos do sexo masculino, bem como para diminuir o escore de mmdai e cicatrização da mucosa em indivíduos do sexo masculino com colite ulcerativa
BR112013014827A2 (pt) 2010-12-13 2016-10-04 Antony Wettstein formulações gástricas e colônicas e métodos para produzir e usar as mesmas
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
NZ702695A (en) 2012-06-19 2015-10-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
EP2877163B1 (en) 2012-07-27 2019-03-20 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
AU2015263938B2 (en) * 2014-05-22 2018-08-30 John Todd Kuenstner Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics
PT3419628T (pt) 2016-02-26 2021-01-05 Debiopharm Int Sa Medicamento para o tratamento de infeções do pé diabético
EP4171546A4 (en) 2020-06-30 2024-03-13 Redhill Biopharma Ltd. FIXED DOSE COMBINATION PRODUCTS OF THREE ANTIBIOTICS, DOSAGE REGIME, METHODS AND KITS FOR TREATMENT OF NON-TUBERCUOUS MYCOBACTERIAL PULMONARY INFECTIONS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
ES2303351T3 (es) 2008-08-01
JP2012126736A (ja) 2012-07-05
CY1109783T1 (el) 2013-09-04
IL132145A (en) 2005-11-20
PT971735E (pt) 2008-06-02
SI0971735T1 (sl) 2008-08-31
ATE389417T1 (de) 2008-04-15
IL132145A0 (en) 2001-03-19
DK0971735T3 (da) 2008-07-07
EP0971735A4 (en) 2004-02-25
DE69839261D1 (de) 2008-04-30
US6277836B1 (en) 2001-08-21
JP2008024713A (ja) 2008-02-07
DE69839261T2 (de) 2009-03-26
JP2001524951A (ja) 2001-12-04
EP0971735A1 (en) 2000-01-19
CA2285923C (en) 2013-03-12
CA2285923A1 (en) 1998-10-08
NZ500696A (en) 2002-05-31
EP0971735B1 (en) 2008-03-19
NO994778L (no) 1999-11-30
NO325947B1 (no) 2008-08-25
WO1998043667A1 (en) 1998-10-08
NO994778D0 (no) 1999-09-30

Similar Documents

Publication Publication Date Title
AR012304A1 (es) Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
ES2183937T3 (es) Inhibidores de la adhesion celular.
PE20040751A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO
BR0109912A (pt) Novas combinações antelmìnticas
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
CR8207A (es) Un conjugado citotoxico ca6 antigeno- especifico y metodos para utilizar el mismo
AR044050A1 (es) Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
ATE445389T1 (de) Liposomale glucocorticoide
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
ES2177671T3 (es) Benzamida enterocinetica.
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
AR019226A1 (es) Uso de texafirinas en enfermedad mediada por macrofagos

Legal Events

Date Code Title Description
FB Suspension of granting procedure